Topic:

M&A

Latest Headlines

Latest Headlines

UPDATED: Actavis bags top 10 Big Pharma status with $66B Allergan buyout

Actavis and Allergan have come to terms on a buyout that values the Botox maker at $66 billion, dwarfing a bid from Valeant and William Ackman that forced the biotech into play. And it gives Actavis CEO Brent Saunders exactly what he's been looking for: Bragging rights to top 10 status in the Big Pharma world--after brushing aside a weakening Eli Lilly.

Another Pfizer run at AZ? Unlikely, Reuters' sources say. But keep an eye on Actavis

With Pfizer's eligibility to bid again for AstraZeneca nearing, the drug giant seems unlikely to make another run at its one-time target, industry-watchers say. But that doesn't mean it isn't prepping a run at someone else.

Why are M&A hedge funds gun shy? Blame AbbVie for killing its Shire deal

AbbVie can count this among the consequences of canceling its Shire buyout: Deal-focused hedge funds are losing investors.

Actavis ready to thwart Valeant with $60B-plus Allergan buyout: Bloomberg

Heads up, Valeant. Actavis is reportedly in talks to snatch up Allergan--and word is it could happen quickly.

Ex-Apple CEO invests in telemedicine

Ex-Apple CEO John Sculley sees the mobile health market as the future patient-preferred healthcare option

WSJ: Pfizer spinoff Zoetis might be Valeant's backup plan if Allergan bid fails

Rumor has it, thanks to potential white knight Actavis, Bill Ackman and Valeant face a serious threat to their Allergan hostile bid. But Ackman may already be preparing for another move.

Medtronic borrows $16B to cover rising costs of Covidien deal

Medtronic's $43 billion acquisition of Covidien has become increasingly expensive, requiring the medical device giant to borrow more than $16 billion, the company said in a massive regulatory filing.

Medtronic makes concessions to European regulator in bid to close Covidien deal

Medtronic submitted concessions to the European Union regulatory commission last Friday. The antitrust authority will decide by Nov. 28 whether to clear the deal.

Shire CEO hints at an upcoming biotech buyout

In an interview with Investor's Business Daily, Shire CEO Flemming Ornskov hints that he'd like to do something similar to the $4.5 billion ViroPharma acquisition, which added a new product to the portfolio while helping spur sales of an existing drug.

Shire CEO happy to fly solo again after AbbVie deal's collapse

Post-Shire-breakup, AbbVie CEO Richard Gonzalez says his company will be scouting about for other "strategic" M&A hookups. But Shire chief Flemming Ornskov isn't interested in courting another buyer.